Century Therapeutics, Inc. (IPSC)
| Market Cap | 285.44M |
| Revenue (ttm) | 4.68M |
| Net Income (ttm) | -127.44M |
| Shares Out | 58.97M |
| EPS (ttm) | -1.97 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 238,660 |
| Open | 4.61 |
| Previous Close | 4.64 |
| Day's Range | 4.58 - 5.00 |
| 52-Week Range | 4.34 - 15.38 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 20.09 (+315.08%) |
| Earnings Date | Mar 16, 2023 |
About IPSC
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refr... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for IPSC stock is "Buy." The 12-month stock price forecast is $20.09, which is an increase of 315.08% from the latest price.
News
Century Therapeutics to Present at Upcoming Investor Conferences
PHILADELPHIA, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun...
5 Health Care Stocks That Are Diving - And May Rally
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
After Plunging -29.84% in 4 Weeks, Here's Why the Trend Might Reverse for Century Therapeutics, Inc. (IPSC)
Century Therapeutics, Inc. (IPSC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street ana...
Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Century Therapeutics closes its Seattle hub amid wider cuts, departure of R&D head
Century Therapeutics is closing its Seattle operations as part of a 25% reduction in headcount and a shift in its priorities.
CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC
Layoffs have been making headlines so far in 2023, even though we're just a few days into the new year. That's true even for gene-editing stocks.
Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026
- Prioritization allows for acceleration of key programs including CNTY-107 in Nectin-4+ tumors, while de-prioritizing further investment in CNTY-103 for glioblastoma -
Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
PHILADELPHIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun...
Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
PHILADELPHIA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun...
Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates
- Preclinical data support next generation platform for iPSC-derived NK cells with multiple gene edits to improve persistence and anti-tumor efficacy -
Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates
Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of 10.17% and 42.11%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for th...
Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell malignancies expected to begin imminently -
Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022
PHILADELPHIA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immu...
Century Therapeutics to Present at the SITC 37th Annual Meeting
PHILADELPHIA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immu...
Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors
PHILADELPHIA, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun...
Century Therapeutics to Present at Chardan's 6th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immu...
Century Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
PHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immu...
Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection
– Investigational New Drug Application for CNTY-101, a CAR-iNK product candidate targeting CD19 for B-cell malignancies, cleared by FDA –
Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates
Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of -8% and 16.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
- Following the recent submission of the IND application for CNTY-101 and pending FDA clearance, the Phase 1 ELiPSE-1 trial in relapsed/refractory lymphoma is on track to commence in the second half o...
Century Therapeutics Announces Its Addition to the Russell Microcap® Index
PHILADELPHIA, June 24, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun...
Century Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium
PHILADELPHIA, June 21, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun...
Century Therapeutics to Host Virtual Research and Development Day on June 13, 2022
PHILADELPHIA, June 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun...
Century Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma expected to commence in the second half of 2022 following IND submission in mid 2022-